KRAS and neoplasm: Apart from the expression of PD-L1 and TMB, there are some specific gene mutations including KRAS/TP53, STK11, EGFR, EPHA, and NOTCH, that are related to efficacy of ICIs by regulating the tumor microenvironment and served as potential biomarkers to predict the clinical benefits of immunotherapy [24–27].